Bicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

Bicara Therapeutics (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors, announced its upcoming participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Tuesday, June 10, 2025, at 3:20 p.m. ET. Investors and interested parties can access the live presentation through the Events and Presentations section of Bicara's Investor Relations website. A recording of the webcast will be made available for later viewing on the company's website.

BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that members of management will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET.

A live webcast of the presentation will be accessible through the Investor Relations section of Bicara’s website under Events and Presentations. A replay of the webcast will be archived and available following the event.

About Bicara Therapeutics
Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a first-in-class bifunctional antibody designed to drive tumor penetration by breaking barriers in the tumor microenvironment that have challenged the treatment of multiple solid tumor cancers. Specifically, ficerafusp alfa combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β). Through this targeted mechanism, ficerafusp alfa reverses the fibrotic and immune-excluded tumor microenvironment driven by TGF-β signaling to enable tumor penetration that drives deep and durable responses. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.

Contacts

Investors
Rachel Frank
IR@bicara.com

Media
Amanda Lazaro
1AB
Amanda@1abmedia.com

FAQ

When is Bicara Therapeutics (BCAX) presenting at the Goldman Sachs Healthcare Conference 2025?

Bicara Therapeutics will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025 at 3:20 p.m. ET.

How can I watch Bicara Therapeutics' (BCAX) presentation at the Goldman Sachs conference?

The presentation can be accessed through the live webcast available in the Events and Presentations section of Bicara's Investor Relations website.

What type of company is Bicara Therapeutics (BCAX)?

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors.

Will there be a replay available of Bicara Therapeutics' (BCAX) Goldman Sachs conference presentation?

Yes, a replay of the webcast will be archived and available on Bicara's website following the event.